Labor Backs Next Gen MRNA Cancer Treatments

VIC Premier

Labor is supporting researchers to bring new cancer treatments closer to clinical trials.

Minister for Economic Development and Medical Research Anthony Carbines today announced two research teams will share $1.98 million through the mRNA Victoria Pipeline grant program.

The University of Melbourne will receive $980,000.

Their project builds on earlier research supported by mRNA Victoria that will investigate how mRNA technology could help immune cells better target solid cancers making CAR T-cell therapies more effective.

The Walter and Eliza Hall Institute of Medical Research (WEHI) will receive $1 million.

This will support the development of potential mRNA treatments for aggressive brain cancers in children and adults.

The mRNA Victoria Pipeline grant program helps researchers progress treatments from pre-clinical research towards Phase 1 clinical trials.

Labor's support of mRNA research is already delivering promising results strengthening Victoria's pipeline of new vaccines and therapies.

This includes, a world-first lupus clinical trial, new treatments for bone marrow failure syndrome with malaria and hepatitis C are also progressing towards clinical trials.

Victoria is proud to be Australia's leading destination for clinical trials.

It is home to around 30 per cent of the nation's clinical trial sites - more than any other state.

Only Labor is backing the research that delivers the next generation of life-saving treatments.

Since 2021, Labor has invested $36 million in 67 RNA research projects through mRNA Victoria.

Supporting researchers and strengthening the state's world-leading RNA research and manufacturing capabilities.

As stated by Minister for Economic Development and Medical Research Anthony Carbines

"We're backing Victoria's world-class researchers to develop new cancer treatments and offer hope to patients here and around the world."

"By advancing cutting-edge research towards clinical trials, we're keeping Victoria at the forefront of medical innovation."

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.